ANTIBODY-UREASE CONJUGATES FOR THERAPEUTIC PURPOSES

(19)

(11)

EP 3 261 678 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	17.03.2021 Bulletin 2021/11

(45)	Mention of the grant of the patent:
	11.11.2020 Bulletin 2020/46

(21)	Application number: 16739870.0

(22)	Date of filing: 22.01.2016

(51)

International Patent Classification (IPC):

A61K 47/50^(2017.01)
C07K 16/30^(2006.01)
C12N 9/80^(2006.01)
A61K 39/395^(2006.01)
A61K 47/68^(2017.01)

A61P 35/00^(2006.01)
C07K 19/00^(2006.01)
C12N 9/96^(2006.01)
C07K 16/28^(2006.01)
A61K 47/64^(2017.01)

(86)	International application number:
	PCT/IB2016/050342

(87)	International publication number:
	WO 2016/116907 (28.07.2016 Gazette 2016/30)

(54)	ANTIBODY-UREASE CONJUGATES FOR THERAPEUTIC PURPOSES ANTIKÖRPER-UREASE-KONJUGATE FÜR THERAPEUTISCHE ZWECKE CONJUGUÉS ANTICORPS-URÉASE POUR DES FINS THÉRAPEUTIQUES

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

23.01.2015 US 201562107210 P

(43)	Date of publication of application:
	03.01.2018 Bulletin 2018/01

(73)	Proprietor: Helix Biopharma Corp.
	Richmond Hill, ON L4B 3J9 (CA)

(72)	Inventors:
	CHAO, Heman Aurora, Ontario L4G 0E5 (CA) WONG, Wah Yau Edmonton, Alberta T5T 5Z8 (CA) TIAN, Baomin Edmonton, Alberta T6W 1N5 (CA) GASPAR, Kimberly Jayne Saskatoon, Saskatchewan S7K 0J7 (CA) KUMAR, Praveen Saskatoon, Saskatchewan S7T 0G1 (CA)

(74)	Representative: Hutter, Anton et al
	Venner Shipley LLP 5 Stirling House Stirling Road The Surrey Research Park Guildford GU2 7RF Guildford GU2 7RF (GB)

(56)

References cited: :

EP-A1- 0 824 019
WO-A1-2004/009112
WO-A1-2014/165985
CA-A1- 2 492 472
CA-A1- 2 908 475

WO-A1-97/15316
WO-A1-2013/185215
CA-A1- 2 130 072
CA-A1- 2 877 505
US-A- 4 762 707

Heman Chao ET AL: "Development of an alkalizing antibody-enzyme conjugate for NSCLC treatment that is in Phase I clinical testing Preclinical Studies Abstract Background Starting Dose Derivations Acknowledgement", L-DOS47 PRESENTATION AT AACR 2013 ANNUAL MEETING, 5 April 2013 (2013-04-05), XP055285609, Retrieved from the Internet: URL:http://www.helixbiopharma.com/wp-conte nt/uploads/2014/02/Helix-BioPharma-AACR.pd f [retrieved on 2016-07-04]
HELIX BIOPHARMA: "L-DOS47: Single domain antibody conjugated anticancer therapy", BIT'S 5TH ANNUAL INTERNATION CONGRESS OF ANTIBODIES, , 1 January 2013 (2013-01-01), pages 1-35, XP009505019, Retrieved from the Internet: URL:http://www.helixbiopharma.com/wp-conte nt/uploads/2014/02/LDOS47-ICA-2013-HZ-.pdf
CHAO H: "DOS47 - Killing cancer by altering the tumor microenvironment", DRUG DELIVERY TECHNOLOGY, DRUG DELIVERY TECHNOLOGY, LLC, US, vol. 11, no. 1, 1 January 2011 (2011-01-01), pages 68-72, XP002763192, ISSN: 1537-2898
CHANDLER H M ET AL: "An investigation of the use of urease-antibody conjugates in enzyme immunoassays", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 53, no. 2, 17 September 1982 (1982-09-17), pages 187-194, XP023900599, ISSN: 0022-1759, DOI: 10.1016/0022-1759(82)90140-5 [retrieved on 1982-09-17]
Sigma: "ANTI-MOUSE IgG (WHOLE MOLECULE) UREASE CONJUGATE", , 6 January 2006 (2006-01-06), pages 1-1, XP055517511, Retrieved from the Internet: URL:https://www.sigmaaldrich.com/content/d am/sigma-aldrich/docs/Sigma/Datasheet/8/u1 004dat.pdf [retrieved on 2018-10-22]
MEYERHOFF M E ET AL: "Electrode-based enzyme immunoassays using urease conjugates", ANALYTICAL BIOCHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 95, no. 2, 1 June 1979 (1979-06-01), pages 483-493, XP024827776, ISSN: 0003-2697, DOI: 10.1016/0003-2697(79)90760-7 [retrieved on 1979-06-01]
AN-PING DENG ET AL: "Application of a polyaniline based ammonium sensor for the amperometric immunoassay of a urease conjugated Tal 1 protein", ANALYTICA CHIMICA ACTA, vol. 461, no. 1, 1 June 2002 (2002-06-01), pages 49-55, XP055517531, AMSTERDAM, NL ISSN: 0003-2670, DOI: 10.1016/S0003-2670(02)00251-9
TIAN ET AL.: 'Production and characterization of a camelid single domain antibody-urease enzyme conjugate for the treatment of cancer' BIOCONJUGATE CHEMISTRY vol. 26, no. 6, 17 June 2015, pages 1144 - 1155, XP055271801 DOI: 10.1021/ACS.BIOCONJCHEM.5B00237
CHAO ET AL.: 'Development of an alkalizing antibody-enzyme conjugate for NSCLC treatment that is in Phase I clinical testing' L-DOS47 PRESENTATION AT AACR 2013 ANNUAL MEETING, [Online] 05 April 2013, pages 1 - 1, XP055285609 Retrieved from the Internet: <URL:HTTP://WWW.HELIXBIOPHARMA.COM/WP-CONTE NT/UPLOADS/2014/02/HELIX-BIOPHARMA-AACR.PDF >
HELIX BIOPHARMA: 'L-DOS47: Single domain antibody conjugated anticancer therapy' BIT'S 5TH ANNUAL INTERNATION CONGRESS OF ANTIBODIES, [Online] 2013, XP009505019 Retrieved from the Internet: <URL:WWW.HELIXBIOPHARMA.COM/WP-CONTENT/UPLO ADS/2014/02/LDOS47-ICA-2013-HZ.PDF>
CHAO: 'DOS47 - Killing cancer by altering the tumor microenvironment' DRUG DEVELOPMENT AND DELIVERY vol. 11, no. 1, 01 January 2011, pages 68 - 72, XP002763192
WONG ET AL.: 'Urease-induced alkalinization of extracellular pH and its antitumor activity in human breast and lung cancers' JOURNAL OF EXPERIMENTAL THERAPEUTICS AND ONCOLOGY vol. 5, no. 2, 01 January 2005, pages 93 - 99, XP009147420

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).